期刊文献+

依折麦布联合氟伐他汀在冠心病降脂疗效中的评价 被引量:10

下载PDF
导出
摘要 目的探讨依折麦布联合氟伐他汀对冠心病患者的降脂作用,并进一步了解其抑制炎症反应的作用,以及对预后的影响。方法将127例确诊冠心病患者用随机单盲法分为两组,依折麦布10 mg联合氟伐他汀40 mg组68例(观察组),单用氟伐他汀剂量40 mg+安慰剂59例(对照组)。随访24周观察调脂疗效及达标率(美国国家胆固醇教育计划成人治疗专家组第三项报告最新版标准)。结果观察组和对照组治疗24周均能显著降低血清总胆固醇、三酰甘油、低密度脂蛋白胆固醇,差异有统计学意义(P<0.05)。低密度脂蛋白胆固醇达标率显著增高,两组间差异有统计学意义(P<0.05)。在降低三酰甘油方面,两组间差异无统计学意义(P>0.05)。治疗期间两组胆红素、红细胞、血小板治疗前后变化不明显,差异无统计学意义(P>0.05),提示观察组耐受性良好。结论冠心病应用依折麦布10 mg联合氟伐他汀40 mg强化治疗,维持治疗24周能有效调脂,提高低密度脂蛋白胆固醇达标率,患者易耐受。
出处 《广东医学》 CAS CSCD 北大核心 2012年第22期3483-3485,共3页 Guangdong Medical Journal
  • 相关文献

参考文献17

  • 1中华人民共和国卫生部.2009年中国卫生统计年鉴目录:2008年城市居民主要疾病死亡率及构成[R/OL]. 2009[2011 -12].http: // www. moh. gov. cn/publicfiles//business/htmlfiles/wsb/index, htm.
  • 2中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5):390-419. 被引量:5230
  • 3K0S0GL0U T,STATKEVICH P, JOHNSON LEVONAS AO, etal. Ezetimibe: a review of its metabolism, pharmacokinetics anddrug interactions[ J] . Clin Pharmacokinet, 2005 , 44(5 ) ; 467 -494.
  • 4DAVIS H H. Ezetimibe: first in a new class of cholesterol absorp-tion inhibitors [ J ]. International Congress Series, 2004,1262 :243 -246.
  • 5PANDOR A, ARA R M, TUMUR L, et al. Ezetimibe monothera-py for cholesterol lowering in2722 people: systematic review andmeta - analysis of randomized controlled trials [ J] . Intern Med,2009, 265(5) : 568 -580.
  • 6SCHOUTEN 0,BOERSMA E,HOEKS S E, et al. Fluvastatinand perioperative events in patients undergoing vascular surgery[J]. N Engl J Med, 2009,361(10) : 980 -989.
  • 7LEE C H, DE FEYTER P,SERRUYS P W,et al. Beneficialeffects of fluvastatin following percutaneous coronary intervention inpatients with unstable and stable angina : results from the Lescolintervention prevention study ( LIPS) [ J] . Heart, 2004 , 90(10):1156-1161.
  • 8孙超,宋娟,田华,赵学梅.氟伐他汀非降脂作用研究进展[J].齐齐哈尔医学院学报,2009,30(4):444-445. 被引量:2
  • 9BALLANTYNE C M. Ezetimibe: efficacy and safety in clinical tri-als [ J ]. Eur Heart J SuppI,2002,4 ( Suppl J) : J9 - J18.
  • 10SAGER P T. Effect of co administration of ezetimibe and simvasta-tin on high - sensitivity C - reactive protein[ J]. Am J Cardiol,2003,92(12) : 1414-1418.

二级参考文献151

共引文献5230

同被引文献88

  • 1俞章平,余晗俏,钟忆周,梁亚非,高文涛.依折麦布联合阿托伐他汀对急性冠状动脉综合征患者血脂指标及血管内皮功能的影响[J].中国生化药物杂志,2014,34(6):110-112. 被引量:24
  • 2李月华,徐琛华,董利军,刘晓红,姜坚.冠心病患者临床表现、血压及血脂水平与血清C反应蛋白的关系[J].中国临床康复,2005,9(27):36-37. 被引量:5
  • 3中华医学会精神病学分会.中国精神障碍分类与诊断标准第三版(精神障碍分类)[J].中华精神科杂志,2001,34(3):184-188.
  • 4Pappadopulos E, Newcomer JW, Kolluri S. Changes itx weight, plasma lipids, and glucose in adults treated with ziprasidone: acomprehensive analysis of pfizer-initiated clinical trials[J]. J Clin Psychiatry, 2012,73 ( 6 ) : e742-748.
  • 5Galletly CA, Foley DL, Waterreus A, et al. Cardiometabolic risk factors in people with psychotic disorders: the second Australian national survey of psychosis[ J]. Aust N Z J Psychiatry, 2012,46 (8) :753-761.
  • 6Garcia-Calvo M, Lisnock J, Bull HG,et al. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPCI L1 ) [ J]. Proc Natl Acad Sci U S A, 2005,102(23) :8132-8137.
  • 7Kaptoge S, Di Angelantonio E, Lowe G, et al. C - reactive protein concentration and risk of coronary heart disease, stroke, and mor- tality: An individual participant meta- analysis[J]. Lancet, 2010, 375(9709) : 132 - 140.
  • 8Tikkanen MJ, Fayyad R, Faergeman O, et al. Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in cor- onary heart disease patients with baseline elevations in alanine aminotransferase levels[J]. Eur Heart J, 2013,34(1) : 679 - 683.
  • 9Boekholdt SM, Arsenault BJ, Hovingh GK, et al. Levels and chan- ges of HDL cholesterol and apolipoprotein AI in relation to risk of cardiovascular events among statin - treated patients a meta - anal- ysis[J]. Circulation, 2013,128(14) : 1504 - 1512.
  • 10Chang CT, Lee JK, Lin JD, et al. The lipid- lowering effect of atorvastatin in Taiwan Residents diabetic patients with hypcrlipidemia [J]. Tzu Chi Medical Journal,2013,25(3) :168 - 174.

引证文献10

二级引证文献91

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部